|
US3060165A
(en)
|
|
1962-10-23 |
|
Preparation of toxic ricin |
|
US498298A
(en)
|
|
1893-05-30 |
|
Range |
|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US5079163A
(en)
|
1985-03-29 |
1992-01-07 |
Cetus Corporation |
Recombinant ricin toxin fragments
|
|
US4689401A
(en)
|
1986-03-06 |
1987-08-25 |
Cetus Corporation |
Method of recovering microbially produced recombinant ricin toxin a chain
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4892827A
(en)
|
1986-09-24 |
1990-01-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5208021A
(en)
|
1987-10-05 |
1993-05-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of preparing diphtheria immunotoxins
|
|
US5792458A
(en)
|
1987-10-05 |
1998-08-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Mutant diphtheria toxin conjugates
|
|
CA1323293C
(en)
|
1987-12-11 |
1993-10-19 |
Keith C. Backman |
Assay using template-dependent nucleic acid probe reorganization
|
|
JP2955759B2
(ja)
|
1988-07-20 |
1999-10-04 |
セゲブ・ダイアグノスティックス・インコーポレイテッド |
核酸配列を増幅及び検出する方法
|
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
|
US5427930A
(en)
|
1990-01-26 |
1995-06-27 |
Abbott Laboratories |
Amplification of target nucleic acids using gap filling ligase chain reaction
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
AU646673B2
(en)
|
1990-05-11 |
1994-03-03 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
|
|
US5608039A
(en)
|
1990-10-12 |
1997-03-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Single chain B3 antibody fusion proteins and their uses
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
US5643578A
(en)
|
1992-03-23 |
1997-07-01 |
University Of Massachusetts Medical Center |
Immunization by inoculation of DNA transcription unit
|
|
AU668384B2
(en)
|
1992-03-12 |
1996-05-02 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release ACTH containing microspheres
|
|
ATE314475T1
(de)
|
1992-06-18 |
2006-01-15 |
Us Gov Health & Human Serv |
Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US5662907A
(en)
|
1992-08-07 |
1997-09-02 |
Cytel Corporation |
Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
|
|
CA2142007C
(en)
|
1992-08-11 |
2007-10-30 |
Robert Glen Urban |
Immunomodulatory peptides
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
US5648211A
(en)
|
1994-04-18 |
1997-07-15 |
Becton, Dickinson And Company |
Strand displacement amplification using thermophilic enzymes
|
|
WO1996002668A1
(en)
|
1994-07-15 |
1996-02-01 |
Azco Nobel N.V. |
Use of rna polymerase to improve nucleic acid amplification process
|
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
AT402203B
(de)
|
1995-06-13 |
1997-03-25 |
Himmler Gottfried Dipl Ing Dr |
Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
EP0780386B1
(en)
|
1995-12-20 |
2002-10-02 |
F. Hoffmann-La Roche Ag |
Matrix metalloprotease inhibitors
|
|
PT885198E
(pt)
|
1996-03-05 |
2002-06-28 |
Astrazeneca Ab |
Derivados de 4-anilinoquinazolina
|
|
DE69718472T2
(de)
|
1996-07-13 |
2003-11-06 |
Glaxo Group Ltd., Greenford |
Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
KR20000067904A
(ko)
|
1996-07-18 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
매트릭스 메탈로프로테아제의 포스피네이트계 억제제
|
|
TW328661B
(en)
|
1996-07-26 |
1998-03-21 |
Oki Electric Ind Co Ltd |
The semiconductor apparatus
|
|
BR9711223A
(pt)
|
1996-08-23 |
1999-08-17 |
Pfizer |
Derivados de cido arilsulfonilamino-hidrox mico
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
EP0950059B1
(en)
|
1997-01-06 |
2004-08-04 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
IL131042A0
(en)
|
1997-02-03 |
2001-01-28 |
Pfizer Prod Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
BR9807824A
(pt)
|
1997-02-07 |
2000-03-08 |
Pfizer |
Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
|
|
KR20000070923A
(ko)
|
1997-02-11 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
아릴설포닐 하이드록삼산 유도체
|
|
DE69832158T2
(de)
|
1997-02-25 |
2006-08-10 |
Arizona Board Of Regents, Tempe |
Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
|
|
WO1998050356A1
(en)
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
AU734009B2
(en)
|
1997-05-30 |
2001-05-31 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
AU8816298A
(en)
|
1997-08-22 |
1999-03-16 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
|
EP1017682A4
(en)
|
1997-09-26 |
2000-11-08 |
Merck & Co Inc |
NEW ANGIOGENESIS INHIBITORS
|
|
WO1999022596A1
(en)
|
1997-11-03 |
1999-05-14 |
Long Roger H |
Attractants for trapping flies
|
|
HUP0100287A3
(en)
|
1997-11-11 |
2003-04-28 |
Pfizer Prod Inc |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
DE19755016A1
(de)
|
1997-12-11 |
1999-06-17 |
Bayer Ag |
Substituierte 2,4-Diamino-1,3,5-triazine
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
US6296843B1
(en)
|
1998-04-03 |
2001-10-02 |
The Penn State Research Foundation |
Mutagenized IL 13-based chimeric molecules
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
CN101227921A
(zh)
|
2003-06-06 |
2008-07-23 |
医学免疫公司 |
EphA4和EphA4调节剂用于诊断、治疗和预防癌症的用途
|
|
KR20060034231A
(ko)
|
2003-06-06 |
2006-04-21 |
메디뮨 인코포레이티드 |
암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
|
|
NZ583292A
(en)
|
2003-11-06 |
2012-03-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
EP1733047A2
(en)
|
2004-02-27 |
2006-12-20 |
Oncotherapy Science, Inc. |
Pin-prc transition genes
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
EP2332970B1
(en)
|
2005-07-29 |
2015-12-23 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services |
Mutated pseudomonas exotoxins with reduced antigenicity
|
|
CN101309933A
(zh)
|
2005-09-07 |
2008-11-19 |
米迪缪尼有限公司 |
毒素偶联的Eph受体抗体
|
|
JP2009531273A
(ja)
*
|
2006-02-28 |
2009-09-03 |
オンコセラピー・サイエンス株式会社 |
抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法
|
|
PT2197903E
(pt)
|
2007-09-04 |
2015-01-02 |
Us Gov Health & Human Serv |
Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
|
|
WO2010141974A1
(en)
*
|
2009-06-10 |
2010-12-16 |
The University Of Melbourne |
Therapeutic applications
|
|
JP2010285413A
(ja)
|
2009-06-10 |
2010-12-24 |
Univ Of Melbourne |
治療用途
|
|
WO2011032022A1
(en)
|
2009-09-11 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved pseudomonas exotoxin a with reduced immunogenicity
|
|
CA2775350A1
(en)
|
2009-09-24 |
2011-03-31 |
Seattle Genetics, Inc. |
Dr5 ligand drug conjugates
|
|
WO2011106723A2
(en)
|
2010-02-26 |
2011-09-01 |
Lpath, Inc. |
Anti-paf antibodies
|
|
WO2012081502A1
(ja)
|
2010-12-17 |
2012-06-21 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
|
|
CN105473591B
(zh)
*
|
2013-07-17 |
2018-02-23 |
香港科技大学 |
作为神经保护剂的EphA4抑制剂
|
|
CN108289930A
(zh)
*
|
2015-07-10 |
2018-07-17 |
香港科技大学 |
用于治疗神经退行性和神经炎性病症的方法和组合物
|
|
CN110769828A
(zh)
*
|
2017-05-12 |
2020-02-07 |
香港科技大学 |
作为epha4抑制剂的杂环化合物
|